On February 7, Kangtai Biological issued an announcement stating that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as "Minhai Biotechnology"), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for its bivalent inactivated enterovirus vaccine (Vero cell) and quadrivalent inactivated enterovirus vaccine (Vero cell). The company will promptly initiate related clinical trials in accordance with the requirements of the approval notice.

The bivalent inactivated enterovirus vaccine (Vero cell) is intended for individuals aged 6 months to 71 months who are susceptible to EV-A71 and CV-A16. It stimulates the body to produce immunity against EV-A71 and CV-A16, and is used to prevent infectious diseases such as hand, foot, and mouth disease (HFMD) caused by enterovirus EV-A71 and CV-A16 infections. The quadrivalent inactivated enterovirus vaccine (Vero cell) is suitable for individuals aged 6 months to 71 months who are susceptible to EV-A71, CV-A6, CV-A10, and CV-A16. It stimulates the body to produce immunity against EV-A71, CV-A6, CV-A10, and CV-A16, and is used to prevent HFMD and other infectious diseases caused by these enteroviruses.

HFMD is a common infectious disease among children, caused by various enterovirus infections. Currently, there are no specific antiviral drugs targeting enterovirus infections. Vaccination remains the most effective and economical measure to prevent HFMD and its large-scale outbreaks. Globally, no bivalent or quadrivalent inactivated enterovirus vaccines (Vero cell) have been approved for market release to date.

https://finance.eastmoney.com/a/202502083314024930.html